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Film dosage forms (FDs) containing allopurinol (AP) were prepared using a casting method with water-soluble polysaccharides,
suchassodiumalginate(ALG),andthereleaseproﬁleofAPfromFDswasinvestigatedinlimiteddissolutionmedium.SomeALGs
were able to form FDs incorporating AP, and the thickness was about 50μm. All FDs were easy to handle, though the rheological
properties varied with ALG species. AP was homogenously present throughout the FDs and was released with disintegration
in 10mL of physiological saline. These results conﬁrmed that FDs are useful for preventing or treating localized problems in
the oral cavity, such as mucositis. FDs are also useful for administering drugs to cancer patients receiving chemotherapy and/or
radiotherapy.
1.Introduction
The xanthine oxidase inhibitor allopurinol (AP) is a drug
used for the treatment of gout. AP has also been used to
prevent and treat oral mucositis (mouth ulcers) in cancer
patients receiving chemotherapy and/or radiotherapy [1–3].
In the treatment of mucositis, direct application of AP to the
oral mucosa is necessary to avoid the systemic action seen
aftergastrointestinalabsorption astheantioxidant activityof
AP will result in lowering the activity of anticancer drug such
asmethotrexate.Forexample,APsuspensions(1mg/mL)are
freshly prepared in the hospital, and the patient gargles with
the preparation [4]. This method for preventing mucositis
is simple and eﬀective; however, these preparations are not
stable for long-term preservation, and it is diﬃcult to control
the amount of AP during gargling, although the dose is not
suﬃciently high to induce systemic eﬀects in the event of
erroneous swallowing.
Recently, oral disintegration (OD) dosage forms such as
OD tablets have become widely utilized, as they are useful
in patients who have diﬃculty swallowing regular tablets
[5, 6]. Film dosage forms (FDs) are also anticipated to be
useful in oral care [7–9] .T h ea c t i v ec o m p o u n dp r e s e n ti n
FDs is spread in the oral cavity as the form disintegrates on
contact with saliva, and the disintegration proﬁle of FDs can
be varied by modifying the ﬁlm base [10]. However, the drug
loading capacity of FDs is typically very low, and the drug
incorporated into FDs should be selected carefully.
FDsaregenerallypreparedusingawater-solublepolymer
base for immediate dissolution in saliva. As various polysac-
charides have been used as additives for drug preparation
or food ingredients because of the safety on peroral admin-
istration, they are candidate materials for FD preparation.
Algal polysaccharide sodium alginate (ALG) consists of α-L-
guluronate and β-D-mannuronate and is able to form thin
ﬁlms[11,12].Pullulan(PUL),apolysaccharidecomposedof
α-D-maltotriose,isalsoaknownﬁlmbase[13].Inthisstudy,
we prepared FDs containing AP using a casting method
with natural polysaccharides without dissolution in organic
solvents, heating, pH regulation, or addition of plasticizer.
The release proﬁles for AP from FDs were then investigated
in limited dissolution medium, as AP is expected to be active
following dissolution in saliva upon oral FD administration.
2.MaterialsandMethods
2.1. Materials. Three species of ALG (300cps, 500cps,
and 1000cps) were obtained from the Nacalai Tesque Inc.2 ISRN Pharmaceutics
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Figure 1: Images of FDs prepared with polysaccharides containing AP.
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Figure 2: Rheological properties of alginate ﬁlms containing AP (n = 3).
(Kyoto, Japan). Low-molecular-weight alginate (L-ALG) was
obtained from Alfa Aesar (Ward Hill, MA, USA). Guluronic-
acid-rich alginate (20G) was supplied by the Kibun Food
Chemifa Co. (Tokyo, Japan). PUL was supplied by the
Hayashibara Biochemical Laboratories (Okayama, Japan).
Polygalacturonic acid (PGA) was purchased from the MP
Biomedicals (Solon, OH, USA). AP was purchased from the
Wako Pure Chemicals (Osaka, Japan). All other chemicals
were of reagent grade.
2.2. FD Preparation. Polysaccharides were dissolved in
deionizedwaterwithagitation,and1.5–4%(W/W)solutions
were prepared. AP (10mg) was added to 10g of the ﬁlm
base solutions, followed by thorough mixing, and 3.0g of
each solution was poured into a plastic Petri dish (diameter,
54mm). After 24h at 37◦C, the circular ﬁlms formed on the
dish were transferred to a desiccator. Film formation was
judged to have failed if a ﬁlm could not be removed from
the bottom of the dish. Film surfaces were observed with a
digital microscope (VHX-900; Keyence Co., Osaka, Japan).
2.3.FilmThicknessandRheologicalProperties. Filmthickness
was measured at 10 points on each ﬁlm using a microm-
eter (CLM1-15QM; Mitutoyo, Kawasaki, Japan) with a setISRN Pharmaceutics 3
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Figure 3: FD surface observed under digital microscope (×50).
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Figure 4: X-ray diﬀractograms. (A)AP (powder); (B)1.5% 300cps
ﬁlm (AP free); (C)1.5% 300 cps ﬁlm containing AP.
pressure of 0.5N. Measurements were made on 3 ﬁlms,
and the mean thickness was calculated for each type. The
rheological properties of each ﬁlm were determined using a
rheometer (SUN RHEO TEX SD-700#; Sun Scientiﬁc Co.,
Tokyo, Japan) at room temperature. The ﬁlm was ﬁxed on
a vial (inner diameter, 1.4mm; outer diameter, 18.8mm)
using joining tape (Scotch mending tape; Sumitomo 3M
Ltd.,Tokyo,Japan)andwasprobedwithacylindricaladapter
(diameter, 5.0mm). Stress and strain were measured at the
point at which the adapter broke through the ﬁlm, and tests
were performed in triplicate.
2.4. X-Ray Diﬀractometry. X-ray diﬀractometry was carried
out using an automatic diﬀractometer (D8 DISCOVER
with GADDS; Bruker AXS K.K., Yokohama, Japan) with a
voltage of 40kV and a current of 40mA. The results of
X-ray diﬀraction were interpreted using computer software
(Bruker AXS K.K.).
2.5. AP Dissolution Test. Physiological saline was used as
the dissolution test medium. Films were placed in a plastic
dish, and 10mL of the dissolution medium preheated to
Table 1: Thickness of FDs containing AP.
Film base Thickness (μm, n = 3)
1.5% 300cps 44 ±1
1.5% 500cps 55 ±9
1.5% 300cps + 0.5% PGA 50 ±3
1.5% 500cps + 0.5% PGA 65 ±12
1.5% 1000cps + 0.5% PGA 48 ±6
37◦C was added. The dish was shaken at 300rpm in a
shaker incubator (SI-300; As One Co., Osaka, Japan) at
37◦C. After 1, 3, 5, 10, 15, 20, 30, 45, and 60minutes,
80μLaliquotswereremovedandplacedintomicro-testtubes
(1.5mL), and 720μL of methanol was added to precipitate
the polysaccharide dissolved from the FD. Samples were
mixed and centrifuged (7,700 × g, 5min; H-1300; Kokusan
Co., Saitama, Japan), and the supernatants were injected into
an HPLC column. All tests were performed in triplicate.
The HPLC system comprised an LC-6A pump (Shimadzu
Co., Kyoto, Japan), a packed column (150mm × 4.6mm,
COSMOSIL 5C18-MS-II, Nacalai Tesque), and a SPD-6A UV
detector (Shimadzu Co.). HPLC for the determination of
AP was conducted at ambient temperature using 20mM
acetate buﬀer (pH 4.5) at a ﬂow rate of 1.0mL/min [14]. The
detector wavelength was set at 254nm.
3. Results and Discussion
Using the casting method, 1.5–2% ALG or 4% PUL was
poured into molds and the solvent was evaporated from the
solution.Thepolysaccharidesusedinthisstudyformcircular
ﬁlms when the solution does not contain AP. In the presence
of AP (1mg/g), both 300cps and 500cps formed circular
ﬁlms, but 1000 cps and PUL did not form ﬁlms, as shown
in Figure 1. On the other hand, all of the polysaccharides
were able to form ﬁlms with the addition of 0.5% PGA to
the ﬁlm base solution, although cracks were observed in the
case of ﬁlms prepared with 4% PUL and 0.5% PGA. The
thicknesses of FDs prepared with ALGs were 44–65μm, as
shown in Table 1. L-ALG (2%) and 20 G (2%) also formed4 ISRN Pharmaceutics
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Figure 5: Release proﬁles of AP from FDs in physiological saline (n = 3).
ﬁlms, and the thicknesses were 48 ± 3μma n d3 7± 2μm,
respectively.TheseresultsindicatethatALGisusefulasaﬁlm
base to prepare FDs incorporating AP.
FDs containing AP are applied to the oral cavity; there-
f o r e ,t h e ym u s tb ee a s yt oh a n d l e .Figure 2 shows the rhe-
ological properties of FDs prepared with ALGs. All ﬁlms
were easy to handle and resistant to tearing, although FD
properties varied with ALG species. Adding 0.5% PGA to
the ﬁlm base solution did not aﬀect FD strength, and no
apparent relationship between ﬁlm thickness and hardness
was observed.
AP is dissolved in the polysaccharide solution, and the
drug is incorporated into the matrix gradually formed by the
polymer base. As shown in Figure 3, AP is homogenously
present throughout the ﬁlm. Therefore, AP would be dis-
tributed across the region to which FD is applied in the oral
cavity.
Figure 4 shows the X-ray diﬀraction patterns for AP
powder and FDs prepared with 1.5% 300cps. AP exhibited
a characteristic crystalline compound diﬀraction pattern.
On the other hand, the diﬀraction pattern of FD was similar
to that of an amorphous polymer, and FD containing AP
showed a diﬀerent pattern than AP powder. These results
indicate that the crystal form of AP is only slightly present in
FDs.
In the treatment of mucositis, solutions or suspensions
of AP are administered in the oral cavity to act directly at
the inﬂammation site. Therefore, AP needs to be released
immediatelyuponcontactwithsaliva,whichissecretedfrom
the salivary glands at 1.5–2.0mL/min after stimulation [15].
In this study, ﬁlms were soaked in 10mL of physiological
saline, and the amount of AP released from the FDs was
measured. In all FDs prepared with ALG, rapid swelling in
the dissolution medium was observed with the naked eye,
andtheﬁlmitselfdissolvedinthemediumwithin20–30min.
As shown in Figure 5, incorporated AP was immediately
released, irrespective of the ALG species used as a ﬁlm base.
In particular, all of the AP was released within 10min
from the FD prepared with 2% 20 G. Similar AP release
proﬁles were obtained with FDs containing PGA. However,
the preparation did not dissolve in physiological saline, and
ﬁlm residue remained at the end of the dissolution test.
These results show that AP is present in the polymer matrix
and is released through pores formed by permeation of the
dissolution medium.
4. Conclusions
FDs allow the distribution of a drug across the region to
which the FD is attached. In this study, FDs were prepared
using natural polysaccharides without addition of plasticiz-
ers or dissolution into organic solvents. FDs prepared with
ALG are able to incorporate AP and immediately release the
drug in limited dissolution medium. FDs are thus useful for
preventing or treating localized problems in the oral cavity,
such as mucositis. They also simplify the administration of
drugs to patients.
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